Smoking Cessation

Nabi receives second U.S. patent on Nicvax

Published in Vaccine Weekly, March 5th, 2003

The U.S. Patent and Trademark Office has issued Nabi Biopharmaceuticals (NABI) U.S. Patent No. 6,518,031, titled "Hapten-Carrier Conjugates for Treating and Preventing Nicotine Addiction."

The patent covers the composition of NicVax, an investigational nicotine conjugate vaccine, the use of the vaccine to obtain antibody, and utilization of the antibody to prevent and treat nicotine addiction.

"The issuance of this second patent on NicVAX further solidifies our proprietary position around this vaccine and provides added momentum to our product development efforts," said David J. Gury, Nabi Biopharmaceuticals chairman and chief executive...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-03-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry